Literature DB >> 15913786

Abnormal subjective experiences of schizophrenia: evaluation of the Eppendorf Schizophrenia Inventory.

Reinhard Mass1, Christian Haasen, Ernst-Jürgen Borgart.   

Abstract

The Eppendorf Schizophrenia Inventory (ESI) is a new clinical questionnaire aimed at self-experienced cognitive disturbances that are considered to be diagnostically specific for schizophrenia. Two ESI validation studies are presented in this report. The aim of study I was to search for objective correlates of the ESI in 100 schizophrenic inpatients. In study II, the diagnostic validity of the ESI was examined by group comparisons (inpatients with first episode or chronic schizophrenia, alcoholism, depression, or obsessive-compulsive disorder, and healthy adults). Study I yielded numerous plausible correlations between ESI subscales and other clinical scales, neuropsychological tests, psychopathological interview data, and neurological symptoms. Study II supported the diagnostic validity of the ESI. A confirmatory factor analysis conducted with the combined schizophrenic sample from both studies corroborated the assumed factor structure. These results confirm the reliability and validity of the ESI.

Entities:  

Mesh:

Year:  2005        PMID: 15913786     DOI: 10.1016/j.psychres.2004.08.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

1.  [Prospective description of the course of psychopathological symptoms in schizophrenia: evaluation of the short form of the Eppendorf Schizophrenia Inventory].

Authors:  R Mass; P E Burek; K Wolf
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

2.  Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link?

Authors:  Saffron Homayoun; Frederique Nadeau-Marcotte; David Luck; Emmanuel Stip
Journal:  Front Psychol       Date:  2011-07-04

3.  Genealogy of instruments for prodrome evaluation of psychosis.

Authors:  Jean-Gabriel Daneault; Emmanuel Stip
Journal:  Front Psychiatry       Date:  2013-04-18       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.